Cancer Care at a Crossroads as India Bets on Precision Medicine

The gathering of oncologists and researchers at the Nextgen Oncology meet in Jodhpur reflects a larger shift underway in India’s approach to cancer care. As treatment moves beyond conventional chemotherapy towards targeted therapy and immunotherapy, the promise of precision medicine is becoming more tangible. Yet, the transition raises as many questions as it answers.

At the heart of this shift is the idea of personalised treatment. Therapies are increasingly being tailored to the genetic profile of both the patient and the tumour. This has the potential to improve outcomes and reduce the harsh side effects long associated with cancer care. For a country where late diagnosis remains a persistent challenge, such advances could redefine survival rates.

However, the benefits of these innovations are unevenly distributed. Access to advanced diagnostics and targeted drugs remains limited to select urban centres and high end institutions. The cost of treatment continues to place it out of reach for a large section of patients. Without a parallel expansion in public health infrastructure and insurance coverage, the gap between what is possible and what is accessible may only widen.

There is also the question of readiness. Precision oncology depends heavily on data, technology, and specialised expertise. India’s healthcare system must invest not only in infrastructure but also in training and research capacity. Collaboration between public institutions and private players will be critical in bridging these gaps.

The Jodhpur conference signals intent. It highlights the growing ambition within India’s medical community to align with global advances. But ambition alone will not suffice. The real test lies in ensuring that innovation does not remain confined to conference halls and elite hospitals.

If India is to confront its rising cancer burden effectively, it must balance cutting edge science with equitable access. The future of oncology cannot be defined solely by technological breakthroughs. It must also be measured by how widely those breakthroughs are shared.